Gynaecomastia — the benign enlargement of glandular breast tissue in males — is more common than many people realise, yet it remains a source of significant embarrassment and distress. Understanding how to get rid of gynaecomastia starts with identifying its underlying cause, whether hormonal, medication-related, or lifestyle-driven. Treatment options range from watchful waiting and lifestyle changes to off-label medications and surgery, depending on severity and duration. This article outlines the causes, available NHS and private treatments, relevant medications, and when to seek medical advice, helping you make informed decisions about managing this condition effectively.

What Is Gynaecomastia and Why Does It Develop?

Gynaecomastia develops due to an imbalance between oestrogen and androgen activity in breast tissue, and may be physiological — occurring at puberty or older adulthood — or caused by medications, underlying conditions, or recreational substances.

Gynaecomastia is the benign enlargement of glandular breast tissue in males, resulting in a firm or rubbery mass beneath the nipple area. It is distinct from pseudogynaecomastia, which refers to fatty tissue accumulation in the chest without true glandular growth — an important distinction because the two conditions have different causes and management pathways.

The condition arises from an imbalance between oestrogen and androgen activity in breast tissue. Oestrogens stimulate glandular proliferation, whilst androgens — primarily testosterone — suppress it. When this balance shifts, either through increased oestrogen levels, reduced androgen levels, or heightened tissue sensitivity, breast tissue can enlarge. This hormonal imbalance may be physiological or pathological in origin.

Physiological gynaecomastia is extremely common and occurs at predictable life stages:

• Neonatal period — due to transplacental oestrogen transfer; typically resolves spontaneously within a few weeks

• Puberty — affecting up to 60% of adolescent males, typically resolving within one to two years

• Older adulthood — associated with declining testosterone levels and increased adipose-related oestrogen conversion

Pathological causes are less common but clinically important. These include:

• Medications — including spironolactone, cimetidine, digoxin, ketoconazole, anabolic steroids, anti-androgens (e.g., bicalutamide), 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride), some antipsychotics (via hyperprolactinaemia), and exogenous oestrogens

• Underlying conditions — including hypogonadism (including Klinefelter syndrome), hyperthyroidism, liver cirrhosis, chronic kidney disease, hyperprolactinaemia, pituitary disease, and rarely oestrogen- or hCG-secreting tumours (including testicular tumours)

• Recreational substances — heavy alcohol use and anabolic steroid misuse are well-recognised contributors; cannabis has been associated with gynaecomastia in some reports, though the evidence remains inconsistent

Understanding the underlying cause is essential before considering any treatment, as addressing the root factor — such as stopping a causative medication — may be sufficient to resolve the condition without further intervention.

Medical and Surgical Treatments Available on the NHS

NHS surgical correction for gynaecomastia is not routinely funded and is classified as low priority; access depends on local ICB policy, with surgery considered only where there is documented psychological harm or functional impairment.

NHS access to treatment for gynaecomastia depends largely on the severity of the condition, its duration, and whether it is causing significant physical or psychological distress. Access to surgical correction is governed by local Integrated Care Board (ICB) commissioning policies and the NHS England Evidence-Based Interventions (EBI) programme, which generally classifies male breast reduction as a low-priority procedure. Routine surgical correction is not routinely funded unless specific clinical criteria are met; patients should check their local ICB policy or ask their GP about Individual Funding Request (IFR) routes where appropriate.

For adolescents, watchful waiting is the standard initial approach, as pubertal gynaecomastia resolves spontaneously in the majority of cases within one to two years. During this period, reassurance and monitoring are typically all that is required. If the condition persists beyond two years or causes considerable psychological impact — such as anxiety, social withdrawal, or avoidance of physical activity — referral to an endocrinologist or specialist may be appropriate.

Where an underlying medical cause is identified, treating that condition takes priority. For example:

• Hypogonadism may be managed with testosterone replacement therapy (TRT) under specialist supervision. It is important to note that TRT can sometimes worsen gynaecomastia in some men through peripheral aromatisation of testosterone to oestrogen; careful specialist risk–benefit assessment is therefore essential before initiating treatment.

• Hyperthyroidism treatment can lead to regression of breast tissue once thyroid function is normalised

• Medication review — if a prescribed drug is identified as the cause, a GP may consider switching to an alternative where clinically safe to do so

Surgical options, including subcutaneous mastectomy (removal of glandular tissue) and liposuction for fatty components, are available privately and, in limited cases, through NHS referral when there is documented psychological harm or functional impairment. Any surgical referral on the NHS would typically follow a thorough endocrine assessment and a period of conservative management.

Patients considering private surgery should ensure their surgeon is listed on the GMC Specialist Register (in Plastic Surgery or General Surgery with a breast interest) and that the facility is registered with and inspected by the Care Quality Commission (CQC). Membership of professional bodies such as BAAPS (British Association of Aesthetic Plastic Surgeons) or BAPRAS may provide additional reassurance. Patients should also be counselled about common surgical risks, including haematoma, scarring, contour irregularity, and changes in nipple sensation.

Medications Used to Treat Gynaecomastia in the UK

No medication is MHRA-licensed for gynaecomastia; tamoxifen and raloxifene are prescribed off-label by specialists and are most effective within the first six to twelve months of onset, before fibrosis occurs.

Pharmacological treatment for gynaecomastia is most effective when initiated early — ideally within the first six to twelve months of onset — before fibrous stromal tissue replaces the more responsive glandular tissue. Once fibrosis has occurred, medications are generally less effective, and surgical intervention may be the only viable option.

It is important to note that no medication is currently licensed by the MHRA specifically for the treatment of gynaecomastia in the UK. Any pharmacological treatment used in this context is therefore prescribed off-label. Off-label prescribing in this setting requires informed consent and should only be initiated and monitored by a specialist, with decisions made on an individual basis weighing potential benefits against risks. Patients should never attempt to source these medicines independently.

The most commonly used agents include:

• Tamoxifen — a selective oestrogen receptor modulator (SERM) that competitively blocks oestrogen receptors in breast tissue. Available evidence suggests it can reduce breast tenderness and, to a lesser extent, tissue volume when used in early-stage gynaecomastia; the strongest evidence relates to improvement in pain and tenderness rather than absolute volume reduction. It is typically prescribed at doses of 10–20 mg daily for three to six months under specialist supervision. Side effects may include hot flushes, mood changes, and, rarely, thromboembolic events.

• Raloxifene — another SERM with a similar mechanism, sometimes used as an alternative; typical off-label dosing is 60 mg once daily. Evidence in gynaecomastia is less extensive than for tamoxifen. Raloxifene also carries a risk of thromboembolic events and should not be assumed to have a superior safety profile without individual clinical assessment.

• Aromatase inhibitors (e.g., anastrozole, letrozole) — these reduce the peripheral conversion of androgens to oestrogens. Their use is largely confined to specialist settings. Evidence is limited and mixed; randomised controlled trials in pubertal gynaecomastia have not demonstrated clear benefit, and aromatase inhibitors are not routinely recommended for this group. They may occasionally be considered in specific adult cases under specialist guidance.

Because side effects are possible with all of these agents, patients should report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. Any pharmacological treatment should only be initiated and monitored by a qualified clinician.

Lifestyle Changes That May Help Reduce Breast Tissue

Lifestyle changes alone cannot eliminate true glandular gynaecomastia, but weight management, resistance and cardiovascular exercise, and avoiding alcohol, anabolic steroids, and cannabis can reduce contributing factors and improve chest contour.

Whilst lifestyle modifications alone are unlikely to eliminate true glandular gynaecomastia, they can play a meaningful supportive role — particularly in cases where pseudogynaecomastia (fatty tissue) is a contributing factor, or where modifiable risk factors are present. Adopting healthier habits may also support overall hormonal balance and reduce the likelihood of progression.

Weight management is one of the most impactful lifestyle changes. Adipose tissue contains the enzyme aromatase, which converts androgens into oestrogens. Excess body fat therefore increases circulating oestrogen levels, which can worsen or perpetuate gynaecomastia. A balanced, calorie-appropriate diet combined with regular physical activity can help reduce adipose-related oestrogen production and improve overall body composition.

In terms of exercise, a combination of:

• Resistance training — to build chest muscle mass and improve overall body composition

• Cardiovascular exercise — to support fat reduction and metabolic health

...is generally recommended. It is important to set realistic expectations: exercise will not directly shrink glandular breast tissue, but it can improve chest contour, posture, and overall body composition.

Avoiding substances associated with gynaecomastia is equally important. These include:

• Cannabis — associated with gynaecomastia in some case reports and observational studies, though the evidence is inconsistent; avoidance is advisable if the condition is a concern

• Alcohol — particularly heavy use, which can suppress testosterone production and, in the context of liver disease, impair the normal metabolism of hormones, leading to elevated oestrogen levels

• Anabolic steroids and performance-enhancing drugs — a well-established cause of gynaecomastia due to aromatisation of exogenous androgens

• Certain herbal supplements — including lavender oil and tea tree oil, which have shown weak endocrine-disrupting activity in some in-vitro studies and case reports; the clinical significance in humans remains uncertain, but avoidance is a reasonable precaution

Addressing these factors early, in conjunction with medical advice, provides the best foundation for managing the condition effectively.

When to See a GP About Gynaecomastia

See a GP if breast enlargement persists beyond three to six months, causes pain or psychological distress, or if a hard, irregular, or rapidly growing lump is present, as urgent referral may be needed to exclude breast cancer.

Many men and adolescents feel embarrassed about gynaecomastia and delay seeking medical advice, sometimes for years. However, early assessment is important — not only to identify any underlying cause that may require treatment, but also to access appropriate support before the condition becomes more established and harder to treat.

You should make an appointment with your GP if:

• Breast tissue enlargement is persistent, progressive, or has been present for more than three to six months

• There is pain, tenderness, or discomfort in the breast area

• You notice a hard, irregular, or rapidly growing lump — this requires prompt assessment to exclude breast cancer, which, whilst rare in males, does occur

• There is nipple discharge, skin changes, or swelling of the lymph nodes

• The condition is causing significant psychological distress, affecting self-esteem, relationships, or daily activities

• You suspect a medication you are taking may be contributing to the problem

Your GP will typically take a thorough medical and medication history, perform a physical examination — including examination of the testes to help exclude a testicular tumour — and arrange relevant blood tests. These may include testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, prolactin, beta-human chorionic gonadotrophin (β-hCG), alpha-fetoprotein (AFP) where a testicular tumour is suspected, thyroid function, and liver and renal function tests. A testicular ultrasound may also be arranged if a testicular cause is suspected.

Where a breast lump has features that are hard, irregular, rapidly enlarging, or associated with nipple discharge or skin changes, your GP should refer you urgently to a breast clinic for assessment under the suspected cancer pathway, in line with NICE guideline NG12 (Suspected cancer: recognition and referral). In the breast clinic, triple assessment — including clinical examination, imaging (mammography and/or ultrasound), and biopsy if indicated — will be carried out as appropriate.

Depending on findings, your GP may also refer you to an endocrinologist, a breast surgeon, or a urologist for further assessment. If psychological distress is prominent, referral to a mental health professional or counselling service may also be appropriate.

The key message is that gynaecomastia is a recognised medical condition — not simply a cosmetic concern — and seeking help early gives you the best chance of an effective outcome.

Frequently Asked Questions